US 12,227,574 B2
Anti-CD3 constructs and uses thereof
Yonglei Shang, Irvine, CA (US); Aude I. Segaliny, Laguna Hills, CA (US); Xiaoya Ma, Laguna Hills, CA (US); Xianzhi Jiang, Laguna Hills, CA (US); and George Wu, Irvine, CA (US)
Assigned to AMBERSTONE BIOSCIENCES, INC., Irvine, CA (US)
Appl. No. 18/570,578
Filed by Amberstone Biosciences, Inc., Laguna Hills, CA (US)
PCT Filed Jun. 16, 2022, PCT No. PCT/US2022/072996
§ 371(c)(1), (2) Date Dec. 14, 2023,
PCT Pub. No. WO2022/266660, PCT Pub. Date Dec. 22, 2022.
Claims priority of provisional application 63/212,024, filed on Jun. 17, 2021.
Claims priority of provisional application 63/305,588, filed on Feb. 1, 2022.
Prior Publication US 2024/0279334 A1, Aug. 22, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01)
CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01)] 19 Claims
 
1. A method of treating a cancer in an individual in need thereof, comprising administering into the individual an anti-CD3 construct, wherein the anti-CD3 construct is a multi-specific construct that comprises 1) an antibody moiety that specifically binds to CD3 (“anti-CD3 antibody moiety”), wherein the anti-CD3 antibody moiety comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, and 2) a second antibody moiety that specifically recognizes a tumor-associated antigen: wherein:
(a) the VH domain comprises (1) a CDR-H1 comprising SYYTH (SEQ ID NO: 5); (2) a CDR-H2 comprising WIYPGDFNTKFNEKFKG (SEQ ID NO: 2); and (3) a CDR-H3 comprising DHYGYYYFDY (SEQ ID NO:12); and the VL domain comprises (1) a CDR-L1 comprising KSSQSLLNSRTRHNYLA (SEQ ID NO: 26); (2) a CDR-L2 comprising WATTRDS (SEQ ID NO: 24); and (3) a CDR-L3 comprising IQSYTGRT (SEQ ID NO: 31),
(b) the VH domain comprises (1) a CDR-H1 comprising SYYYH (SEQ ID NO: 6); (2) a CDR-H2 comprising WIYPGDFNTKFNEKFKG (SEQ ID NO: 2); and (3) a CDR-H3 comprising DHYGYYYFDY (SEQ ID NO:12); and the VL domain comprises (1) a CDR-L1 comprising KSSQSLLNSRTRHNYLA (SEQ ID NO: 26); (2) a CDR-L2 comprising WATTRDS (SEQ ID NO: 24); and (3) a CDR-L3 comprising IQSYTGRT (SEQ ID NO: 31),
(c) the VH domain comprises (1) a CDR-H1 comprising SYYYH (SEQ ID NO: 6); (2) a CDR-H2 comprising WIYPGDFNTKFNEKFKG (SEQ ID NO: 2); and (3) a CDR-H3 comprising DHYGYYYFDY (SEQ ID NO:12); and the VL domain comprises (1) a CDR-L1 comprising KSSQSLLNSRTRHNYLA (SEQ ID NO: 26); (2) a CDR-L2 comprising WATTRAS (SEQ ID NO: 28); and (3) a CDR-L3 comprising IQSYTGRT (SEQ ID NO: 31),
(d) the VH domain comprises (1) a CDR-H1 comprising SYYTH (SEQ ID NO: 5); (2) a CDR-H2 comprising WIYPGDFNTKFNEKFKG (SEQ ID NO: 2); and (3) a CDR-H3 comprising DHYGYYYFDY (SEQ ID NO:12); and the VL domain comprises (1) a CDR-L1 comprising KSSQSLLNSRTRHNYLA (SEQ ID NO: 26); (2) a CDR-L2 comprising WATTRDS (SEQ ID NO: 24) or WATTRAS (SEQ ID NO: 28); and (3) a CDR-L3 comprising IQSYTGRT (SEQ ID NO: 31);
(e) the VH domain comprises (1) a CDR-H1 comprising SYYYH (SEQ ID NO: 6); (2) a CDR-H2 comprising WIYPGDFNTKFNEKFKG (SEQ ID NO: 2); and (3) a CDR-H3 comprising DHYHQYYFDY (SEQ ID NO:13); and the VL domain comprises (1) a CDR-L1 comprising KSSQSLLNSRTRHNYLA (SEQ ID NO: 26); (2) a CDR-L2 comprising WATTRAS (SEQ ID NO: 28); and (3) a CDR-L3 comprising IQSYTGRT (SEQ ID NO: 31); or
(f) the VH domain comprises (1) a CDR-H1 comprising SYYYH (SEQ ID NO: 6); (2) a CDR-H2 comprising WIYPGDFNTKFNEKFKG (SEQ ID NO: 2); and (3) a CDR-H3 comprising DHYHQYYFDY (SEQ ID NO: 14); and the VL domain comprises (1) a CDR-L1 comprising KSSQSLLNSRTRHNYLA (SEQ ID NO: 26); (2) a CDR-L2 comprising WATTRAS (SEQ ID NO: 28); and (3) a CDR-L3 comprising IQSYTGRT (SEQ ID NO: 31).